Table 2.

Cytokine-Targeted Drugs

Drugs	Type	Clinical Outcomes
Infliximab	TNF-α inhibitor	ClinicalTrials.gov, NCT00056264 (In the treatment of COPD, infliximab has a higher probability of causing lung malignancy) ClinicalTrials.gov, NCT00244192 (6 weeks of treatment in COPD patients, had not any evidence pointed that it can improve clinical outcomes)
Etanercept	TNF-α inhibitor	ClinicalTrials.gov, NCT00789997 (It can improve lung function in COPD patients, it was less compared to prednisolone)
Mepolizumab	IL-5 inhibitor	ClinicalTrials.gov, NCT02105948, NCT02105961 (It can reduce COPD exacerbation with elevated eosinophils)
Benralizumab	IL-5 inhibitor	ClinicalTrials.gov, NCT02138916, NCT02155660 (Addition of benralizumab does not reduce annual exacerbation rates in patients with moderate or severe COPD with a history of frequent exacerbations)
MK-7123	CXCR2 inhibitor	ClinicalTrials.gov NCT01006616 (It can significantly improves lung function in COPD patients treated by 50mg dose)